Patent ID: 9612236
Date: 2017-04-04
CPC Classifications: G01N

Claim:
1. A method for detecting prostate-specific antigen in an affinity assay, the method comprising the steps of: a) providing a biological sample volume containing the prostate-specific antigen at a concentration of from at 4 to 10 ng/ml; b) adding PSA-10 antibody capturing moiety to the biological sample volume, wherein the PSA-10 antibody capturing moiety captures the prostate-specific antigen and is adhered to a magnetic particle, wherein the PSA-10 antibody capturing moiety is linked to the particle via a linker comprising a DNA linker consisting of 48 base pairs of double stranded DNA followed by 10 bases of single stranded DNA, wherein the DNA is digestable by a DNAse and cleavable for specific elution with EcoRI; c) concentrating the captured prostate-specific antigen by magnetic particle separations into an elution volume of less than 5 μL that is at least eighty times smaller than the biological sample volume in step a) in a time of fifteen minutes; d) cleaving the prostate-specific antigen from the particle, wherein at least 30% of the prostate-specific antigen is cleaved from the particle using a DNAse or EcoRI; e) binding the prostate-specific antigen to a modified PSA-36 antibody capturing moiety associated with a reagent and to a modified PSA-66 antibody capturing moiety comprising a tag, wherein a portion of the PSA-10 antibody capturing moiety that was cleaved from the particle binds to one of the modified antibodies, and f) at least one of detecting and quantifying the prostate-specific antigen in an affinity assay format, wherein the tag binds to a fourth capturing moiety on a detection surface.